Cargando…
Females present higher dose‐adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males
Females present a higher risk of adverse drug reactions. Sex‐related differences in drug concentrations may contribute to these observations but they remain understudied given the underrepresentation of females in clinical trials. The aim of this study was to investigate whether anthropometric and s...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175982/ https://www.ncbi.nlm.nih.gov/pubmed/36864560 http://dx.doi.org/10.1111/cts.13497 |
_version_ | 1785040334906982400 |
---|---|
author | Hindi, Jessica Pilon, Marc‐Olivier Meloche, Maxime Leclair, Grégoire Oussaïd, Essaïd St‐Jean, Isabelle Jutras, Martin Gaulin, Marie‐Josée Mongrain, Ian Busseuil, David Rouleau, Jean Lucien Tardif, Jean‐Claude Dubé, Marie‐Pierre de Denus, Simon |
author_facet | Hindi, Jessica Pilon, Marc‐Olivier Meloche, Maxime Leclair, Grégoire Oussaïd, Essaïd St‐Jean, Isabelle Jutras, Martin Gaulin, Marie‐Josée Mongrain, Ian Busseuil, David Rouleau, Jean Lucien Tardif, Jean‐Claude Dubé, Marie‐Pierre de Denus, Simon |
author_sort | Hindi, Jessica |
collection | PubMed |
description | Females present a higher risk of adverse drug reactions. Sex‐related differences in drug concentrations may contribute to these observations but they remain understudied given the underrepresentation of females in clinical trials. The aim of this study was to investigate whether anthropometric and socioeconomic factors and comorbidities could explain sex‐related differences in concentrations and dosing for metoprolol and oxypurinol, the active metabolite of allopurinol. We conducted an analysis of two cross‐sectional studies. Participants were self‐described “White” adults taking metoprolol or allopurinol selected from the Montreal Heart Institute Hospital Cohort. A total of 1007 participants were included in the metoprolol subpopulation and 459 participants in the allopurinol subpopulation; 73% and 86% of the participants from the metoprolol and allopurinol subpopulations were males, respectively. Females presented higher age‐ and dose‐adjusted concentrations of both metoprolol and oxypurinol (both p < 0.03). Accordingly, females presented higher unadjusted and age‐adjusted concentration:dose ratio of both metoprolol and allopurinol/oxypurinol compared to males (all p < 3.0 × 10(−4)). Sex remained an independent predictor of metoprolol concentrations (p < 0.01), but not of oxypurinol concentrations, after adjusting for other predictors. In addition to sex, age, daily dose, use of moderate to strong CYP2D6 inhibitors, weight, and CYP2D6 genotype‐inferred phenotype were associated with concentrations of metoprolol (all p < 0.01). Daily dose, weight, estimated glomerular filtration rate (eGFR), and employment status were associated with oxypurinol concentrations (all p < 0.01). Females present higher dose‐adjusted concentrations of metoprolol and oxypurinol than males. This suggests the need for sex‐specific dosing requirements for these drugs, although this hypothesis should be validated in prospective studies. |
format | Online Article Text |
id | pubmed-10175982 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101759822023-05-13 Females present higher dose‐adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males Hindi, Jessica Pilon, Marc‐Olivier Meloche, Maxime Leclair, Grégoire Oussaïd, Essaïd St‐Jean, Isabelle Jutras, Martin Gaulin, Marie‐Josée Mongrain, Ian Busseuil, David Rouleau, Jean Lucien Tardif, Jean‐Claude Dubé, Marie‐Pierre de Denus, Simon Clin Transl Sci Research Females present a higher risk of adverse drug reactions. Sex‐related differences in drug concentrations may contribute to these observations but they remain understudied given the underrepresentation of females in clinical trials. The aim of this study was to investigate whether anthropometric and socioeconomic factors and comorbidities could explain sex‐related differences in concentrations and dosing for metoprolol and oxypurinol, the active metabolite of allopurinol. We conducted an analysis of two cross‐sectional studies. Participants were self‐described “White” adults taking metoprolol or allopurinol selected from the Montreal Heart Institute Hospital Cohort. A total of 1007 participants were included in the metoprolol subpopulation and 459 participants in the allopurinol subpopulation; 73% and 86% of the participants from the metoprolol and allopurinol subpopulations were males, respectively. Females presented higher age‐ and dose‐adjusted concentrations of both metoprolol and oxypurinol (both p < 0.03). Accordingly, females presented higher unadjusted and age‐adjusted concentration:dose ratio of both metoprolol and allopurinol/oxypurinol compared to males (all p < 3.0 × 10(−4)). Sex remained an independent predictor of metoprolol concentrations (p < 0.01), but not of oxypurinol concentrations, after adjusting for other predictors. In addition to sex, age, daily dose, use of moderate to strong CYP2D6 inhibitors, weight, and CYP2D6 genotype‐inferred phenotype were associated with concentrations of metoprolol (all p < 0.01). Daily dose, weight, estimated glomerular filtration rate (eGFR), and employment status were associated with oxypurinol concentrations (all p < 0.01). Females present higher dose‐adjusted concentrations of metoprolol and oxypurinol than males. This suggests the need for sex‐specific dosing requirements for these drugs, although this hypothesis should be validated in prospective studies. John Wiley and Sons Inc. 2023-03-02 /pmc/articles/PMC10175982/ /pubmed/36864560 http://dx.doi.org/10.1111/cts.13497 Text en © 2023 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Hindi, Jessica Pilon, Marc‐Olivier Meloche, Maxime Leclair, Grégoire Oussaïd, Essaïd St‐Jean, Isabelle Jutras, Martin Gaulin, Marie‐Josée Mongrain, Ian Busseuil, David Rouleau, Jean Lucien Tardif, Jean‐Claude Dubé, Marie‐Pierre de Denus, Simon Females present higher dose‐adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males |
title | Females present higher dose‐adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males |
title_full | Females present higher dose‐adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males |
title_fullStr | Females present higher dose‐adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males |
title_full_unstemmed | Females present higher dose‐adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males |
title_short | Females present higher dose‐adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males |
title_sort | females present higher dose‐adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175982/ https://www.ncbi.nlm.nih.gov/pubmed/36864560 http://dx.doi.org/10.1111/cts.13497 |
work_keys_str_mv | AT hindijessica femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales AT pilonmarcolivier femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales AT melochemaxime femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales AT leclairgregoire femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales AT oussaidessaid femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales AT stjeanisabelle femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales AT jutrasmartin femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales AT gaulinmariejosee femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales AT mongrainian femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales AT busseuildavid femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales AT rouleaujeanlucien femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales AT tardifjeanclaude femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales AT dubemariepierre femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales AT dedenussimon femalespresenthigherdoseadjusteddrugconcentrationsofmetoprololandallopurinoloxypurinolthanmales |